Exercise ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	10

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05239611 (ClinicalTrials.gov)	February 14, 2022	10/1/2022	Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis	Feasibility of Home-based ExerciseProgram for Adults With Cystic Fibrosis to Improve Patient-centere ...	Cystic Fibrosis	Drug: Exercise	University of Kansas Medical Center	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
2	NCT04039087 (ClinicalTrials.gov)	September 5, 2019	28/7/2019	Sildenafil Exercise: Role of PDE5 Inhibition	Mechanisms of Exercise Intolerance in Cystic Fibrosis: Role of PDE5 Inhibition	Cystic Fibrosis	Drug: Sildenafil 40mg oral capsule;Drug: Placebo Oral capsule	National Jewish Health	Augusta University;Cystic Fibrosis Foundation	Recruiting	9 Years	N/A	All	40	Phase 2/Phase 3	United States
3	NCT03522831 (ClinicalTrials.gov)	May 1, 2018	19/3/2018	CF Bronchodilation	A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspne ...	Lung Diseases;Cystic Fibrosis	Drug: Salbutamol;Drug: Placebo	University of British Columbia	NULL	Active, not recruiting	19 Years	N/A	All	20	N/A	Canada
4	NCT02875366 (ClinicalTrials.gov)	September 2016	15/8/2016	A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on ExerciseTolerance in Subjects With Cysti ...	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Luma ...	Cystic Fibrosis	Drug: LUM/IVA;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	N/A	All	70	Phase 4	Australia;United Kingdom
5	EUCTR2016-000066-34-GB (EUCTR)	24/06/2016	25/07/2017	A Study of the Effects of Lumacaftor/Ivacaftor on ExerciseTolerance in Subjects With Cystic Fibrosis ...	A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Luma ...	Cystic fibrosis in patients homozygous for the F508del-CFTR Mutation MedDRA version: 20.0;Level: PT; ...	Trade Name: Orkambi Product Name: lumacaftor/ivacaftor Product Code: VX-809/VX-770 INN or Proposed INN: ...	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	66	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Australia;United Kingdom
6	NCT02057458 (ClinicalTrials.gov)	April 2014	4/2/2014	Blood Flow and Vascular Function in Cystic Fibrosis	Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis	Cystic Fibrosis	Drug: Sildenafil (Acute-1 hour);Drug: Sildenafil (Subchronic-4 weeks);Drug: Placebo	Augusta University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	N/A	All	19	Phase 2	United States
7	NCT01937325 (ClinicalTrials.gov)	February 2014	4/9/2013	CPET in CF Patients With One G551D Mutation Taking VX770	Airway Infection, Inflammatory Markers and ExerciseCapacity in Patients With Cystic Fibrosis and at ...	Cystic Fibrosis	Drug: ivacaftor;Drug: placebo	The Alfred	NULL	Active, not recruiting	16 Years	70 Years	Both	20	Phase 4	Australia
8	NCT01772758 (ClinicalTrials.gov)	August 2011	16/10/2012	Cystic Fibrosis and Endothelial Function: At Rest and During Exercise	Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise	Cystic Fibrosis	Drug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant Cocktail	Augusta University	NULL	Completed	7 Years	N/A	All	64	Phase 2	United States
9	NCT00434278 (ClinicalTrials.gov)	March 2007	11/2/2007	A Trial of Pulmozyme Withdrawal on ExerciseTolerance in Cystic Fibrosis Subjects With Severe Lung Di ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercis ...	Cystic Fibrosis	Drug: Dornase alfa;Drug: placebo	Genentech, Inc.	NULL	Terminated	14 Years	N/A	All	27	Phase 4	United States
10	NCT00164021 (ClinicalTrials.gov)	February 2001	13/9/2005	The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lun ...	The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before a ...	Cystic Fibrosis	Procedure: Physiotherapy, exercise, percutaneous gastrostomy feeds;Drug: Anti-reflux pharmacotherapy ...	Bayside Health	The Alfred;Monash University	Recruiting	16 Years	70 Years	Both	180	N/A	Australia

First Previous1Next Last